Journal
/
/
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
JoVE Journal
Medicine
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Medicine
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
DOI:

11:02 min

October 30, 2013

, , , , , , ,

Chapters

  • 00:05Title
  • 01:43Bladder Cancer Induction and Vaccination Treatments
  • 02:49Monitoring and Sample Collection
  • 04:11Multiplex Fluorometric Microbead Immunoassay
  • 06:37IFN-γ/IL-4 ELISpot Preparation and Analysis
  • 08:07Representative Transitional Cell Bladder Carcinoma Induction Results
  • 10:39Conclusion

Summary

Automatic Translation

An N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder cancer model was developed in human mucin 1 (MUC1) transgenic mice for the purpose of testing MUC1-directed immunotherapy. After administering a MUC1-targeted peptide vaccine, a cytotoxic T lymphocyte response to MUC1 was confirmed by measuring serum cytokine levels and T-cell specific activity.

Related Videos

Read Article